Evaluation and Management of Periodic Paralysis from Dyselectrolytemia
For patients presenting with periodic paralysis and dyselectrolytemia, immediately distinguish between hypokalemic periodic paralysis (HPP) and non-HPP using spot urine testing, as this fundamentally changes management—HPP requires minimal potassium replacement (0.5-1.0 mEq/kg) to avoid dangerous rebound hyperkalemia, while non-HPP requires aggressive potassium repletion for large total body deficits.
Initial Diagnostic Approach
The critical first step is differentiating HPP (potassium shift into cells) from non-HPP (true potassium depletion), as misdiagnosis leads to improper and potentially dangerous treatment 1, 2.
Key Diagnostic Tests
Obtain these before initiating therapy:
- Spot urine potassium concentration: <20 mmol/L suggests HPP 1
- Transtubular potassium gradient (TTKG) and potassium-creatinine ratio: These reliably distinguish HPP from non-HPP 1
- Arterial blood gas: Absence of metabolic acid-base disorder suggests HPP; metabolic alkalosis or acidosis favors non-HPP 2
- ECG monitoring: Essential for both hypo- and hyperkalemia complications 3, 4
A very low urine potassium excretion rate with normal acid-base status indicates HPP, while high urinary potassium with metabolic disturbances indicates non-HPP 2.
Acute Management of Hypokalemic Periodic Paralysis
Potassium Replacement Strategy
For HPP, use conservative dosing:
- Oral route preferred: 0.5-1.0 mEq/kg potassium chloride 5
- Intravenous route (if necessary): Use mannitol as solvent, NEVER glucose 6
Critical Pitfall: Rebound Hyperkalemia
63% of HPP patients develop rebound hyperkalemia (>5 mmol/L) despite receiving only 63±36 mmol of potassium chloride 1. This occurs because HPP involves potassium redistribution, not true depletion 7. Monitor potassium levels closely during and after replacement.
Acute Management of Non-HPP
For true potassium depletion (gastrointestinal/renal losses):
- Higher doses of potassium chloride required to replete large total body deficits 2
- Address underlying cause (diarrhea, vomiting, renal losses)
- Correct concurrent hypomagnesemia, which impairs potassium repletion 4
Management of Hyperkalemic Periodic Paralysis
While less common, hyperkalemic forms present with brief attacks (<12 hours) typically in the first decade of life 8.
Acute Hyperkalemia with Cardiotoxicity
For severe hyperkalemia (>6.5 mmol/L) with ECG changes or cardiac arrest, follow this sequence 3, 4:
Stabilize cardiac membrane immediately:
Shift potassium intracellularly (temporary, may need repeating):
- Insulin 10 units + glucose 25g (50 mL D50) IV over 15-30 minutes
- Nebulized albuterol 10-20 mg over 15 minutes
- Sodium bicarbonate 50 mEq IV over 5 minutes (if metabolic acidosis present) 4
Promote potassium excretion:
- Furosemide 40-80 mg IV (if adequate renal function)
- Sodium polystyrene sulfonate (Kayexalate) 15-50g with sorbitol
- Hemodialysis for refractory cases 4
Important caveat: IV bolus potassium administration for cardiac arrest in suspected hypokalemia is NOT recommended and may be harmful 3.
ECG Recognition Patterns
Hyperkalemia progression 4:
- Peaked T waves (earliest sign)
- Flattened/absent P waves
- Prolonged PR interval
- Widened QRS complex
- Sine-wave pattern → cardiac arrest
Hypokalemia 4:
- U waves
- T-wave flattening
- Ventricular arrhythmias (especially with digoxin)
Chronic Prophylactic Management
For Hypokalemic Periodic Paralysis
Carbonic anhydrase inhibitors are first-line prophylaxis 5, 8:
- Acetazolamide or dichlorphenamide
- Potassium-sparing diuretics as alternatives
- Note: These prevent attacks but have little value acutely 5
Trigger Avoidance 5:
- Rest after exercise (most important precipitating factor)
- High carbohydrate meals
- Excessive sodium intake
- Consider potassium prophylaxis before known triggers
Safety Measures 5:
Always keep potassium, water, and telephone at bedside, regardless of current weakness status
Special Considerations
Perioperative Management 5:
- Check clinical status frequently
- Avoid glucose-containing IV fluids
- Have potassium replacement immediately available
Thyrotoxic Periodic Paralysis
This is an important secondary cause requiring specific attention 8, 7:
- Treat underlying hyperthyroidism definitively
- Particularly vigilant monitoring for rebound hyperkalemia 7
- Can occur in non-Asian populations 8
Medication-Induced Hyperkalemia 9
For patients on RAASi therapy (ACE inhibitors, ARBs, MRAs) who develop hyperkalemia:
- Do not automatically discontinue RAASi given mortality/morbidity benefits 10
- Classify severity: mild (>5.0-<5.5 mEq/L), moderate (5.5-6.0 mEq/L), severe (>6.0 mEq/L) 9
- Consider newer potassium binders to allow RAASi continuation 10
- Reassess potassium within 1 week after intervention 10
Prognosis and Monitoring
While often considered benign, periodic paralysis can cause 8:
- Respiratory distress (requires immediate intervention)
- Permanent myopathy
- Cardiac arrhythmias during crises
- Death during paralysis
Correct diagnosis and immediate treatment are crucial for preventing these complications 8.